The most frequently used targeted therapies for mucosal melanomas are BRAF and MEK inhibitors, which can be administered in combination, e.g., brafenib plus tramatinib, especially in patients with a BRAF V600 mutation [117,160]. The gene discussed is MAP2K7; the disease is melanoma.